At 25RevolAI, we don't just build AI-powered systems. We design them to operate safely, predictably, and with absolute compliance in the world's most critical industries. Our publications offer deep-dive analyses, operational blueprints, and honest perspectives on the realities of scaling AI where the stakes are highest.
Dave Stephens, Operating Partner
A postmortem of last year's Illumina False Claims Act settlement, further connections to FDA's emerging questions about AI, and why the durable answer is to eliminate whole classes of attestation risk instead of managing them all.
Steve Lupo, Chief Innovation Officer
The industry’s letter on open-weight AI makes a sound case to policymakers. It leaves operational questions open. Sovereignty, lifecycle control, and total cost of ownership are settled by architecture, not by licensing.
Dave Stephens, Operating Partner
A postmortem of the first FDA enforcement action citing artificial intelligence, what the federal accountability standard now means for the private sector, and why the answer is not a black box.
